Related Experiment Video
Updated: Aug 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients
1Cardiovascular Research Center, National Yang-Ming University School of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Insights
Statin withdrawal in hypercholesterolemic patients led to rebound lipid profiles and hsCRP levels, but matrix metalloproteinase (MMP) levels remained stable or decreased, suggesting a prolonged statin effect.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
Background:
- Serum matrix metalloproteinase (MMP) levels are linked to outcomes in coronary artery disease.
- The impact of statin withdrawal on MMP levels is not well understood.
Purpose of the Study:
- To investigate the changes in serum MMP-2, MMP-3, MMP-9, tissue inhibitor of MMP (TIMP), and highly sensitive C-reactive protein (hsCRP) after simvastatin withdrawal in hypercholesterolemic patients.
Main Methods:
- Sixty-one hypercholesterolemic patients on simvastatin had statin discontinued.
- Lipid profiles, MMPs, TIMP, and hsCRP were measured at baseline and 120 days post-withdrawal.
- Control groups included untreated hyperlipidemia patients and healthy individuals.
Main Results:
- Lipid profiles and hsCRP rebounded significantly 120 days after statin withdrawal.
- Serum MMP-2 and MMP-9 levels remained unchanged.
- Serum MMP-3 levels decreased significantly post-statin withdrawal (P=0.022).
- Variations in all measured parameters were inversely correlated with baseline levels.
Conclusions:
- Short-term statin discontinuation differentially affects serum hsCRP and MMPs.
- MMP levels remained stable or decreased despite lipid and hsCRP rebound, indicating a potential prolonged statin effect.
- Further research is needed to clarify the clinical implications of these findings.
Background:
Serum matrix metalloproteinase (MMP) levels have been related to clinical outcomes in patients with coronary artery disease. Though statin treatment might reduce serum MMPs the change of levels after statin withdrawal remains obscure.
Materials And Method:
Sixty-one consecutive hypercholesterolaemic patients whose lipid profiles had been well controlled by regular simvastatin (20 mg day(-1)) treatment for more than 6 months were enrolled. Statin was discontinued after their lipid profiles reached the treatment goal of the ATP-III guideline. The lipid profiles, serum MMP-2, MMP-3 and MMP-9, tissue inhibitor of MMP and highly sensitive C-reactive protein (hsCRP) levels were measured on the day of simvastatin withdrawal and 120 days later. A further 50 hyperlipidaemia patients who had never received statin treatment (positive control group) and 28 healthy patients with normal lipid profiles (negative control group) were also studied as control groups.
Results:
While the lipid profiles had been normalized, the levels of serum inflammatory markers were still higher in hypercholesterolaemic patients than in the healthy subjects. Up to 120 days after statin withdrawal there was no coronary event, but the lipid profiles and serum hsCRP levels had significantly rebounded in study patients. However, serum MMP-2 and MMP-9 levels remained unchanged and the MMP-3 level was even further reduced after statin withdrawal (115.04 +/- 84.54 vs. 92.71 +/- 66.71 ng mL(-1), P = 0.022). Moreover, the amplitudes of variation (%) of each parameter including MMPs, TIMP, hsCRP and lipid profiles after statin withdrawal were inversely correlated to their respective baseline levels before withdrawal (r = -0.702 to -0.284; P < 0.005).
Conclusions:
The effects of short-term discontinuation of statin were different on serum hsCRP and MMPs levels in hypercholesterolaemic patients. While lipid profiles and serum hsCRP level had rebounded the serum MMPs levels were still unchanged, or even reduced, suggesting the prolonged effect of statin treatment, especially on serum MMP-3 level up to 120 days after simvastatin withdrawal. Further work is required to clarify the situation both in terms of these serum markers and clinical effects.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Role of Matrix Metalloproteases in Degradation of ECM
A...
Cholesterol: Significance and Regulation
Considering cholesterol and...